ストックスクリーナーアプリを入手
1.17
1.74%
0.02
プレマーケット:
1.18
0.01
+0.85%
前日終値:
$1.15
開ける：
$1.13
24時間の取引高:
181.43K
Relative Volume:
0.84
時価総額：
$12.06M
収益：
$200.00K
当期純損益:
$-11.37M
株価収益率:
-0.4243
EPS:
-2.7573
ネットキャッシュフロー:
$-10.27M
1週間 パフォーマンス:
+2.63%
1か月 パフォーマンス:
-4.88%
6か月 パフォーマンス:
-24.52%
1年 パフォーマンス:
-43.20%
1日の値動き範囲:
$1.13
$1.18
1週間の範囲:
$1.10
$1.18
52週間の値動き範囲:
$1.00
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Compare SNGX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.17 | 11.85M | 200.00K | -11.37M | -10.27M | -2.7573 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-07-28 | ダウングレード | Dawson James | Buy → Neutral |
| 2018-01-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 繰り返されました | Maxim Group | Buy |
| 2017-07-17 | 開始されました | H.C. Wainwright | Buy |
Soligenix Inc (SNGX) 最新ニュース
Soligenix secures EU orphan drug designation for Behçet’s disease therapy - MSN
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Hedge Fund Bets: Can Soligenix Inc be the next market leader2026 Top Decliners & Long-Term Safe Return Strategies - baoquankhu1.vn
Mycosis Fungoides Treatment Market Surges to US$ 3.42 Billion - openPR.com
Aug Chart Watch: What is the next catalyst for Soligenix IncBond Market & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Technical Analysis: Can Soligenix Inc be the next market leader2026 Dividend Review & AI Enhanced Trading Signals - baoquankhu1.vn
SNGX: Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data - TradingView — Track All Markets
SNGX: Interim Analysis for Phase 3 CTCL Study in 2Q26 - Zacks Small Cap Research
Stock Recap: Is Soligenix Inc a speculative investmentPortfolio Update Report & Reliable Entry Point Alerts - baoquankhu1.vn
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy - The Globe and Mail
[EFFECT] SOLIGENIX, INC. SEC Filing - Stock Titan
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy - Sahm
Soligenix (SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy - NewMediaWire
Soligenix (SNGX) Announces Positive Study Results for HyBryte in CTCL Treatment - GuruFocus
Positive Clinical Results from HyBryte™ Comparative Study Evalua - GuruFocus
HyBryte study shows faster response vs Valchlor in lymphoma trial By Investing.com - Investing.com Canada
HyBryte study shows faster response vs Valchlor in lymphoma trial - Investing.com
Soligenix (SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results - NewMediaWire
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results - TipRanks
Soligenix reports 2025 results, eyes Q2 trial data By Investing.com - Investing.com South Africa
Soligenix Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Soligenix (NASDAQ: SNGX) registers 1,054,688 resale shares from warrants - Stock Titan
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Soligenix (SNGX) 2025 10-K outlines CTCL, psoriasis and vaccine programs - Stock Titan
Buybacks Report: Can Soligenix Inc grow without external funding2026 Volatility Report & Safe Entry Trade Reports - baoquankhu1.vn
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results - Bitget
Soligenix reports 2025 results, eyes Q2 trial data - Investing.com
Soligenix announces recent accomplishments and year end 2025 financial results - marketscreener.com
Soligenix Announces Recent Accomplishments And Year End 2025 Financial Results - TradingView
Retail Trends: What analysts say about Soligenix Inc stockGold Moves & Free Community Supported Trade Ideas - baoquankhu1.vn
Aug Sectors: Is Soligenix Inc a strong candidate for buy and holdMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Soligenix, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Guidance Update: Will Soligenix Inc benefit from rising consumer demand2026 Highlights & AI Forecasted Stock Moves - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
Soligenix receives EU orphan drug status for Behçet’s treatment By Investing.com - Investing.com South Africa
Soligenix (SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behcet Disease - NewMediaWire
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease - Benzinga
Soligenix (SNGX) Gains EU Orphan Drug Designation for Dusquetide in Behcet's Disease - GuruFocus
Soligenix receives EU orphan drug status for Behçet’s treatment - Investing.com
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease - Lelezard
SNGX: Late-stage rare disease therapies and vaccines show strong clinical and commercial promise - TradingView — Track All Markets
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behcet's Disease - Bitget
Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - NewMediaWire
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - TradingView
Soligenix Inc (SNGX) 財務データ
収益
当期純利益
現金流量
EPS
0.45%
0.77%
大文字化:
|
ボリューム (24 時間):